Should I buy or sell ARS Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ARS Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SPRY shares. View SPRY analyst ratings or view top-rated stocks .

What is ARS Pharmaceuticals' stock price target for 2024?

4 analysts have issued twelve-month price targets for ARS Pharmaceuticals' stock. Their SPRY share price targets range from $18.00 to $19.00. On average, they predict the company's stock price to reach $18.50 in the next year. This suggests a possible upside of 122.1% from the stock's current price. View analysts price targets for SPRY or view top-rated stocks among Wall Street analysts .

How have SPRY shares performed in 2024?

ARS Pharmaceuticals' stock was trading at $5.48 at the beginning of the year. Since then, SPRY shares have increased by 52.0% and is now trading at $8.33. View the best growth stocks for 2024 here .

Are investors shorting ARS Pharmaceuticals?

ARS Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 5,500,000 shares, an increase of 29.4% from the March 15th total of 4,250,000 shares. Based on an average trading volume of 643,600 shares, the short-interest ratio is presently 8.5 days. Approximately 13.1% of the shares of the stock are short sold. View ARS Pharmaceuticals' Short Interest .

When is ARS Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our SPRY earnings forecast .

How were ARS Pharmaceuticals' earnings last quarter?

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) released its quarterly earnings data on Thursday, March, 21st. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.07.

How do I buy shares of ARS Pharmaceuticals?

Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SPRY

ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free SPRY Stock Alerts

$8.47

+0.03 (+0.36%)

(As of 04:21 PM ET)

Compare

Today's Range: $8.25
▼
$8.65
50-Day Range: $7.01
▼
$10.22
52-Week Range: $2.55
▼
$11.27

Volume: 487,833 shs
Average Volume: 619,907 shs
Market Capitalization: $817.36 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.50

Get ARS Pharmaceuticals alerts:

ARS Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 122.1% Upside
$18.50 Price Target
Short Interest: Bearish
13.13% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.66
Based on 8 Articles This Week
Insider Trading: Acquiring Shares
$8.92 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.69) to ($0.34) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.10 out of 5 stars

Medical Sector

325th out of 918 stocks

Pharmaceutical Preparations Industry

139th out of 417 stocks

3.5

Analyst's Opinion

Consensus Rating
ARS Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
ARS Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
13.13% of the float of ARS Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
ARS Pharmaceuticals has a short interest ratio ("days to cover") of 8.5.
Change versus previous month
Short interest in ARS Pharmaceuticals has recently increased by 29.41%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
ARS Pharmaceuticals does not currently pay a dividend.
Dividend Growth
ARS Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SPRY.

3.7

News and Social Media Coverage

News Sentiment
ARS Pharmaceuticals has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for ARS Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
12 people have searched for SPRY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
10 people have added ARS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ARS Pharmaceuticals insiders have bought 93.34% more of their company's stock than they have sold. Specifically, they have bought $8,917,946.00 in company stock and sold $4,612,480.00 in company stock.
Percentage Held by Insiders
35.60% of the stock of ARS Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
68.16% of the stock of ARS Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for ARS Pharmaceuticals are expected to grow in the coming year, from ($0.69) to ($0.34) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ARS Pharmaceuticals is -14.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ARS Pharmaceuticals is -14.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ARS Pharmaceuticals has a P/B Ratio of 3.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About ARS Pharmaceuticals Stock (NASDAQ:SPRY)

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

SPRY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SPRY Stock News Headlines

April 18, 2024 | insidertrades.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sarina Tanimoto Sells 100,000 Shares

April 11, 2024 | insidertrades.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CEO Richard E. Lowenthal Sells 100,000 Shares

April 19, 2024 | Behind the Markets (Ad)

Forget NVIDIA, buy this $2 AI stock now…

This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.

March 28, 2024 | insidertrades.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Purchases $3,964,656.00 in Stock

March 27, 2024 | insidertrades.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $21,133.86 in Stock

March 22, 2024 | insidertrades.com

Richard E. Lowenthal Sells 1,918 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

April 19, 2024 | americanbankingnews.com

Sarina Tanimoto Sells 100,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

April 19, 2024 | americanbankingnews.com

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 3.4% on Insider Selling

April 19, 2024 | Behind the Markets (Ad)

Forget NVIDIA, buy this $2 AI stock now…

This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.

April 19, 2024 | investing.com

Ars Pharmaceuticals CEO sells over $928k in company stock

April 15, 2024 | americanbankingnews.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Short Interest Up 29.4% in March

April 12, 2024 | americanbankingnews.com

Richard E. Lowenthal Sells 100,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

April 12, 2024 | investing.com

Ars Pharmaceuticals CEO sells shares worth over $927k

April 12, 2024 | investing.com

Ars pharmaceuticals exec sells shares worth over $927k

April 3, 2024 | markets.businessinsider.com

ARS Pharma Submits Addl. Data In Response To FDA's CRL For Neffy

April 3, 2024 | finance.yahoo.com

Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

April 3, 2024 | globenewswire.com

ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)

March 31, 2024 | 247wallst.com

Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO

March 25, 2024 | markets.businessinsider.com

Buy Rating on ARS Pharmaceuticals Amid Strong neffy Approval Prospects and Indication Expansion

March 21, 2024 | finance.yahoo.com

ARS Pharmaceuticals Inc (SPRY) Reports Full Year and Q4 2023 Financial Results

March 21, 2024 | globenewswire.com

ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

March 7, 2024 | globenewswire.com

ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day

March 6, 2024 | realmoney.thestreet.com

ARS Pharmaceuticals just upgraded at Leerink, here's why

March 6, 2024 | globenewswire.com

ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024

February 26, 2024 | markets.businessinsider.com

ARS Pharma's Neffy Shows Rapid Symptom Control In Phase 2 Urticaria Clinical Study

February 26, 2024 | globenewswire.com

ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study

February 22, 2024 | globenewswire.com

ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024

See More Headlines

Receive SPRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SPRY
CUSIP: N/A
CIK: 1671858
Web: ars-pharma.com
Phone: 206-456-2900
Fax: N/A
Employees: 24
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $18.50
High Stock Price Target: $19.00
Low Stock Price Target: $18.00
Potential Upside/Downside: +118.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.57)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-54,370,000.00
Net Margins: N/A
Pretax Margin: -181,216.67%
Return on Equity: -22.24%
Return on Assets: -21.50%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 96.92
Quick Ratio: 96.92

Sales & Book Value

Annual Sales: $30,000.00
Price / Sales: 27,245.17
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.40 per share
Price / Book: 3.53

Miscellaneous

Outstanding Shares: 96,500,000
Free Float: 62,147,000
Market Cap: $817.36 million
Optionable: Optionable
Beta: 0.83

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Richard Lowenthal M.B.A. (Age 58)
M.S., MSMSEL, Founder, President, CEO & Director
Comp: $908.83k
Dr. Sarina Tanimoto M.B.A. (Age 56)
M.D., Co-Founder & Chief Medical Officer
Comp: $748.97k
Mr. Eric Karas (Age 52)
Chief Commercial Officer
Comp: $618.61k
Dr. Robert Bell Ph.D.
Co-Founder & Chief Science Officer
Ms. Kathleen D. Scott CPA
Chief Financial Officer
Mr. Brian T. Dorsey M.S. (Age 55)
Chief Operations Officer
Mr. Alexander A. Fitzpatrick Esq. (Age 57)
Chief Legal Officer & Secretary
Mr. Daniel Relovsky
Senior Vice President of Marketing
Mr. Harris Kaplan M.B.A. (Age 72)
Executive Vice President of Commercial Strategy
Mr. Justin Chakma (Age 34)
Chief Business Officer & Secretary

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SPRY Stock Analysis - Frequently Asked Questions

Should I buy or sell ARS Pharmaceuticals stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ARS Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SPRY shares.
View SPRY analyst ratings or view top-rated stocks.
What is ARS Pharmaceuticals' stock price target for 2024?: 4 analysts have issued twelve-month price targets for ARS Pharmaceuticals' stock. Their SPRY share price targets range from $18.00 to $19.00. On average, they predict the company's stock price to reach $18.50 in the next year. This suggests a possible upside of 122.1% from the stock's current price.
View analysts price targets for SPRY or view top-rated stocks among Wall Street analysts.
How have SPRY shares performed in 2024?: ARS Pharmaceuticals' stock was trading at $5.48 at the beginning of the year. Since then, SPRY shares have increased by 52.0% and is now trading at $8.33.
View the best growth stocks for 2024 here.
Are investors shorting ARS Pharmaceuticals?: ARS Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 5,500,000 shares, an increase of 29.4% from the March 15th total of 4,250,000 shares. Based on an average trading volume of 643,600 shares, the short-interest ratio is presently 8.5 days. Approximately 13.1% of the shares of the stock are short sold.
View ARS Pharmaceuticals' Short Interest.

When is ARS Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our SPRY earnings forecast.
How were ARS Pharmaceuticals' earnings last quarter?: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) released its quarterly earnings data on Thursday, March, 21st. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.07.
How do I buy shares of ARS Pharmaceuticals?: Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SPRY) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial